Online inquiry

IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2243MR)

This product GTTS-WQ2243MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Lama glama
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2243MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10172MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ13665MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ3419MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ4455MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ14062MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ809MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ8043MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ12173MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW